Response to Pembrolizumab in a Patient with Relapsing Thymoma

The interaction of programmed death ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) results in critical inhibition of the immune system. 1 Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010; 37: 430-439 Abstract Full Text Full Text PDF PubMed Scopus (228) Google Scholar PD-L1 expression was recently reported in thymic epithelial tumors (TETs) and associated with aggressive histologic subtype and poor prognosis. 2 Padda S.K. Riess J.W. Schwartz E.J. et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J. Thorac Oncol. 2016; 10: 500-508 Abstract Full Text Full Text PDF Scopus (91) Google Scholar , 3 Katsuya Y. Fujita Y. Horinouchi H. Ohe Y. Watanabe S ichi Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015; 88: 154-159 Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar